TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00807339

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation
Description: Dose escalation three consecutive treatments

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyberKnife Robotic Radiosurgery System
Study: NCT01063998

Intervention type: OTHER
Intervention: Urine Marker
Description: Urinary KIM-1 measurements
Study: NCT03292185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.6 mg Liraglutide, single dose administration under the skin in the thigh
Study: NCT00517023

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sleuth Implantable Loop Recorder
Description: ILR insertion under aseptic conditions in left pectoral region (local anaesthetic procedure only)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sleuth Implantable Loop Recorder
Description: ILR insertion under aseptic conditions in left pectoral region (local anaesthetic procedure only)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other
Description: Routine care and tests usually offered for syncope patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Other
Description: Routine care and tests usually offered for syncope patients.
Study: NCT03176147

Intervention type: OTHER
Intervention: Iron deficiency anemia
Description: The prevalence of iron deficiency anemia is determined at T3 (after 34 SA). The predictive factors for this anemia will be sought according to the data collected in T1.
Study: NCT01353118

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: gastric bypass
Description: Optimise glucose control within 3 months before operation
Study: NCT03292185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.6 mg Liraglutide, single dose administration under the skin in the thigh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.6 mg Liraglutide, single dose administration under the skin in the thigh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.6 mg Liraglutide, single dose administration under the skin in the thigh
Study: NCT03030677

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pectoralis II block & catheter without Lidocaine dissection
Description: B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pectoralis II block & catheter with Lidocaine dissection
Description: B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. 10 ml of lidocaine 1% will be injected for plan dissection to facilitate the procedure. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures

Intervention type: OTHER
Group type: OTHER
Intervention: catheter insertion
Description: catheter insertion after Lidocaine dissection

Intervention type: OTHER
Group type: OTHER
Intervention: catheter insertion
Description: catheter insertion after Lidocaine dissection
Study: NCT00650819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Simvastatin
Description: ezetimibe 10 mg plus simvastatin 20 mg once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: simvastatin 20 mg plus ezetimibe placebo once daily for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10 mg plus simvastatin placebo once daily for 8 weeks
Study: NCT01900041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantovigar
Description: 1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.

Intervention type: DRUG
Group type: OTHER
Intervention: Minoxidil 2% only
Description: 1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil 2% only
Description: 1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.
Study: NCT03790852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSI-301
Description: Intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSI-301
Description: Intravitreal injection
Study: NCT03421379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon Nasal Powder
Description: Administered intranasally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon Hydrochloride Solution
Description: Administered IM
Study: NCT03571607

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
Study: NCT04000126

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pupil reflex dilation measurement (PRD)
Description: Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupil reflex dilation measurement (PRD)
Description: Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pupil reflex dilation measurement (PRD)
Description: Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PPI (Pupillary Pain Index)
Description: Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPI (Pupillary Pain Index)
Description: Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PPI (Pupillary Pain Index)
Description: Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: 1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100ml 0,9% NaCl iv 10min before intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral Index (BIS)
Description: Bispectral Index will be monitored to assess the depth of anaesthesia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Description: Bispectral Index will be monitored to assess the depth of anaesthesia

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bispectral Index (BIS)
Description: Bispectral Index will be monitored to assess the depth of anaesthesia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HR
Description: HR in beats/min will be measured by the electrocardiogram monitor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR
Description: HR in beats/min will be measured by the electrocardiogram monitor

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HR
Description: HR in beats/min will be measured by the electrocardiogram monitor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BP
Description: BP will be measured automatically by an occluding upper arm cuff

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BP
Description: BP will be measured automatically by an occluding upper arm cuff

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BP
Description: BP will be measured automatically by an occluding upper arm cuff
Study: NCT02106351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.
Study: NCT02770235

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DE assessment
Description: by a validated self-administered questionnaire: Index International erectile function (IIEF-15)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AGE measurement
Description: By AGE-ReaderTM
Study: NCT01972412

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: telephone support
Description: Telephone support for four months about healthy diet, physical activity and medication use.
Study: NCT00726180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab (Herceptin®)
Description: About 1 week (4 - 7 days) before scheduled breast surgery, consisting of lumpectomy or mastectomy, subjects will receive a dose of trastuzumab (Herceptin®). Trastuzumab will be given through an IV or port for approximately 90 minutes. During this time, subjects will be closely monitored by a chemotherapy nurse to make sure that subjects do not have a reaction to the medication. It is possible that the infusion of the medication will need to be slowed down, in which case, the time for the infusion will be longer than 90 minutes. The one dose of the trastuzumab drug will be provided by the study (not billed to insurance), but the charges to administer the drug will be billed to subjects or subjects health insurance.
Study: NCT02536105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate HCl ER tablets 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate HCl ER tablets 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate HCl ER for suspension
Study: NCT04406714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trial Mailed FIT Intervention - Age Group 50-75
Description: Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in an envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sub-Study Mailed FIT Intervention Enhanced Envelope - Age Group 45-49
Description: Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in an enhanced envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. The enhanced envelope is a yellow padded envelope with a USPS tracking label and sticker message: Important information from your doctor. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sub-Study Mailed FIT Active Comparator Plain Envelope - Age Group 45-49
Description: Subjects are mailed an introductory letter advising them that they will receive a FIT kit in the mail. Next, subjects are mailed a FIT packet in plain envelope that contains a cover letter, CRC information sheet, FIT instruction sheet, and FIT kit with a pre-paid return envelope. The plain envelope is a white envelope without a USPS tracking label or sticker message. Subjects receive up to two mailed letters reminding them to complete and return the FIT. Subjects receive FIT results via letter or phone call.
Study: NCT01787006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, 5-FU
Description: 5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 of cycle 1 and 2, 750mg/m2/day as continuous infusion on day 1-4 of cycle 3 and 4~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin, 5-FU
Description: 5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 of cycle 1 and 2, 750mg/m2/day as continuous infusion on day 1-4 of cycle 3 and 4~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery.
Study: NCT02081378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib (ABL001)
Description: Asciminib was be administered orally in a dose escalation schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib (ABL001)
Description: Asciminib was be administered orally in a dose escalation schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib (ABL001)
Description: Asciminib was be administered orally in a dose escalation schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib (ABL001)
Description: Asciminib was be administered orally in a dose escalation schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib (ABL001)
Description: Asciminib was be administered orally in a dose escalation schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Asciminib and Nilotinib was administered orally in CML patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Asciminib and imatinib was administered orally in CML patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Asciminib and dasatinib was administered orally in CML patients
Study: NCT01944436

Intervention type: DRUG
Intervention: Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)

Intervention type: DRUG
Intervention: Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)
Study: NCT05452915

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological (NPA)
Description: The neuropsychological assessment consists of following tests and questionnaires:~* Wechsler Adult Intelligence Scale (WAIS)-III: Digit-Symbol-Coding (Coding)~* WAIS-IV: Digit Span, Matrix reasoning~* Delis-Kaplan Executive Function Scale (D-KEFS): Color-Word Test, Word Fluency Test~* Ruff 2 \& 7~* MapCog Spectra~Questionnaires:~* EuroQoL five dimensions questionnaire (EQ5D)~* Hospital Anxiety and Depression Scale (HADS)~* Insomnia Severity Index (ISI)~* Multidimensional Fatigue Inventory-20 (MFI-20)~* Multidimensional Pain Inventory (MPI)~* Screening questions on physical activity~* Visual analogue scale on fatigue (VAS-f) before and after NPA~* Visual analogue scale on fatigue (VAS-f) and pain before and after the fMRI scanning.~* Pain level, experienced during the NPA, will be rated (0-10) at the end of the session

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological (NPA)
Description: The neuropsychological assessment consists of following tests and questionnaires:~* Wechsler Adult Intelligence Scale (WAIS)-III: Digit-Symbol-Coding (Coding)~* WAIS-IV: Digit Span, Matrix reasoning~* Delis-Kaplan Executive Function Scale (D-KEFS): Color-Word Test, Word Fluency Test~* Ruff 2 \& 7~* MapCog Spectra~Questionnaires:~* EuroQoL five dimensions questionnaire (EQ5D)~* Hospital Anxiety and Depression Scale (HADS)~* Insomnia Severity Index (ISI)~* Multidimensional Fatigue Inventory-20 (MFI-20)~* Multidimensional Pain Inventory (MPI)~* Screening questions on physical activity~* Visual analogue scale on fatigue (VAS-f) before and after NPA~* Visual analogue scale on fatigue (VAS-f) and pain before and after the fMRI scanning.~* Pain level, experienced during the NPA, will be rated (0-10) at the end of the session

Intervention type: OTHER
Intervention: Imaging
Description: Imaging (24 patients + 22 controls):~BOLD resting-state before and after 20-min vigilance task (e-prime). During the vigilance task, fMRI is performed.~Clinical protocol:~1. High-resolution T1-weighted.~2. High-resolution T2-weighted Scan (FLAIR).

Intervention type: OTHER
Intervention: Imaging
Description: Imaging (24 patients + 22 controls):~BOLD resting-state before and after 20-min vigilance task (e-prime). During the vigilance task, fMRI is performed.~Clinical protocol:~1. High-resolution T1-weighted.~2. High-resolution T2-weighted Scan (FLAIR).

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory biomarkers
Description: Blood samples from inflammatory biomarkers will be taken on 36 patients and 36 controls. Everyone who undergoes imaging will undergo blood tests.

Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory biomarkers
Description: Blood samples from inflammatory biomarkers will be taken on 36 patients and 36 controls. Everyone who undergoes imaging will undergo blood tests.
Study: NCT04881214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: pulmonary rehabilitation for 12 weeks, 3 times a week. control will take place at 3, 6 and 12 months
Study: NCT04001556

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Minor Salivary gland Biopsy
Description: Minor salivary gland biopsy with injection of lidocain

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ARFI
Description: Acoustic Radiation Force Impulse on Major Salivary Glands

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ARFI
Description: Acoustic Radiation Force Impulse on Major Salivary Glands

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MSG US
Description: Ultrasonography of Major Salivary Glands

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MSG US
Description: Ultrasonography of Major Salivary Glands
Study: NCT01897051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin + propranolol
Description: 1. Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~2. Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol + Placebo
Description: 1. Placebo of Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~2. Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared.
Study: NCT04090346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Fecal Microbiota Transplant (FMT) is a procedure to replace beneficial bacteria which has been killed or suppressed in the colon.
Study: NCT02300870

Intervention type: DRUG
Intervention: Optison
Description: Echocardiogram with IV contrast

Intervention type: DRUG
Intervention: Optison
Description: Echocardiogram with IV contrast
Study: NCT02105194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: total body exposure to greater than atmospheric pressure oxygen
Study: NCT01326247

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: thermal waters nasal irrigation
Description: The first group (group 1) has practiced crenotherapy with hyper-mineral chloride sodium water aerosol by nasal adapter for 15 days per month, for three consecutive months, at thermal spa services of Lacco Ameno, while the control group (group 2) was treated, in the same period, daily, by a micronized nasal douche with 0.9% NaCl (isotonic) solution.
Study: NCT02141191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled hypertonic saline (7%)
Description: Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled hypertonic saline (7%)
Description: Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device
Study: NCT04478162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supporting parents who have premature babies to be ready for discharge with the training given within the scope of FICare model.
Description: At least 1 week of FICare training for parents At least 4 hours of training on FICare for health professionals Trainings will be held between 13:30 and 15:30 in a training room with heat, light and seating arrangement (for parents who are not able to participate in the training during the week, trainings will be held at the appropriate time interval on the weekend .) Premature baby dummy on oral care, eye care, nose care, ear care, skin care, bath, attired in clothes,/removal, safe sleeping baby, safe transport, kangaroo care (physical contact), non-invasive drug application will be shown and the parents also will be asked to implement,
Study: NCT02797028

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanidins capsule
Description: Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months